Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Shares Shorted: Short Interest Up 264.3% in September

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 93,732 shares, an increase of 264.3% from the September 15th total of 25,732 shares. Based on an average daily volume of 1,091 shares, the short-interest ratio is currently 85.9 days.

Hansa Biopharma AB (publ) Stock Performance

Shares of Hansa Biopharma AB (publ) stock remained flat at $3.29 during midday trading on Friday. The business’s 50 day moving average price is $3.63 and its 200 day moving average price is $3.17. Hansa Biopharma AB has a 12 month low of $2.90 and a 12 month high of $3.70.

Analyst Ratings Changes

Separately, Danske began coverage on shares of Hansa Biopharma AB (publ) in a report on Tuesday, June 16th. They issued a “buy” rating on the stock. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.